Luterman M, Iwamoto T, Gagnon C
Research Laboratory, Royal Victoria Hospital, McGill University, Montreal, Canada.
Int J Androl. 1991 Apr;14(2):91-8. doi: 10.1111/j.1365-2605.1991.tb01070.x.
The origin of a human seminal-plasma sperm-motility inhibitor was investigated. Seminal vesicle and prostatic fluids, testes, epididymides, prostate and seminal vesicles were collected from young cadavers. The motility inhibitor, as measured by its capacity to block the motility of demembranated-reactivated sperm was present in significant amounts only in seminal vesicle fluid. The level of biological activity in this fluid was 13.6-fold higher than in seminal plasma. However, the concentration of motility inhibitor, as measured by ELISA, using an antibody generated against the motility inhibitor purified from human seminal plasma, was only 1.54-fold higher than in seminal plasma. The data suggest that the seminal plasma motility inhibitor originates from seminal vesicle fluid and that it is processed into a nine-fold less biologically active form when seminal vesicle fluid is mixed with other accessory gland secretions at ejaculation.
对人类精浆中精子活力抑制剂的来源进行了研究。从年轻尸体上采集了精囊和前列腺液、睾丸、附睾、前列腺和精囊。通过其阻断去膜再活化精子活力的能力来测定的活力抑制剂,仅在精囊液中大量存在。该液体中的生物活性水平比精浆中的高13.6倍。然而,使用针对从人类精浆中纯化的活力抑制剂产生的抗体,通过酶联免疫吸附测定法(ELISA)测量的活力抑制剂浓度仅比精浆中的高1.54倍。数据表明,精浆活力抑制剂起源于精囊液,并且在射精时精囊液与其他附属腺分泌物混合时,它会被加工成生物活性降低九倍的形式。